Down-Regulation of CXXC5 De-Represses MYCL1 to Promote Hepatic Stellate Cell Activation

Xiaoyan Wu1,2,3,4†, Wenhui Dong†, Ming Kong†, Haozhen Ren1,2, Jinglin Wang1,2, Longcheng Shang†, Zhengyi Zhu†, Wei Zhu* and Xiaolei Shi1,2*

1 Department of Hepatobiliary Surgery, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2 Hepatobiliary Institute of Nanjing University, Nanjing, China, 3 Institute of Biomedical Research, Liaocheng University, Liaocheng, China, 4 Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Translational Medicine, and Center for Experimental Medicine, Department of Pathophysiology, Nanjing Medical University, Nanjing, China, 5 Department of Anesthesiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Liver fibrosis is mediated by myofibroblasts, a specialized cell type involved in wound healing and extracellular matrix production. Hepatic stellate cells (HSC) are the major source of myofibroblasts in the fibrotic livers. In the present study we investigated the involvement of CXXC-type zinc-finger protein 5 (CXXC5) in HSC activation and the underlying mechanism. Down-regulation of CXXC5 was observed in activated HSCs compared to quiescent HSCs both in vivo and in vitro. In accordance, over-expression of CXXC5 suppressed HSC activation. RNA-seq analysis revealed that CXXC5 influenced multiple signaling pathways to regulate HSC activation. The proto-oncogene MYCL1 was identified as a novel target for CXXC5. CXXC5 bound to the proximal MYCL1 promoter to repress MYCL1 transcription in quiescent HSCs. Loss of CXXC5 expression during HSC activation led to the removal of CpG methylation and acquisition of acetylated histone H3K9/H3K27 on the MYCL1 promoter resulting in MYCL1 trans-activation. Finally, MYCL1 knockdown attenuated HSC activation whereas MYCL1 over-expression partially relieved the blockade of HSC activation by CXXC5. In conclusion, our data unveil a novel transcriptional mechanism contributing to HSC activation and liver fibrosis.

Keywords: transcriptional regulation, epigenetics, transcription repressor, liver fibrosis, hepatic stellate cells, DNA methylation

INTRODUCTION

Liver fibrosis is a key intermediate step in such irreversible liver diseases as hepatocellular carcinoma and cirrhosis (Luedde and Schwabe, 2011). Liver fibrosis is mediated primarily by myofibroblasts, a morphologically and functionally distinctive cell type specialized in the synthesis of extracellular matrix (ECM) proteins (Lee Y.A. et al., 2015). Myofibroblasts are
Mechanistically, CXXC5 binds to the Dishevelled protein to null mice display accelerated subcutaneous wound healing. It remains to be determined whether and, if so, how CXXC5 may promote the proliferation, migration, and invasion of liver cancer cells. On the contrary, Tan et al. (2018) have implicated CXXC5 in the development of hepatocellular carcinoma (HCC), a pathology intimately associated with liver fibrosis. Y an et al. (2018) have reported that CXXC5 antagonizes HSC activation. We therefore hypothesized that CXXC5 might regulate HSC trans-differentiation. We report here that CXXC5 expression is down-regulated during HSC activation. CXXC5 binds to the promoter region of MYCL1, a proto-oncogene, and represses MYCL1 transcription. Loss of proteins, comprising DNA methyltransferases, DNA demethylases, histone methyltransferases, and histone demethylases, that contribute to transcriptional regulation by preferentially binding to unmethylated CpG islands (Long et al., 2013). Recently, two independent investigations have implicated CXXC5 in the development of hepatocellular carcinoma (HCC), a pathology intimately associated with liver fibrosis. Yan et al. (2018) have reported that CXXC5 antagonizes HCC development by promoting TGF-β inducing cell cycle arrest of liver cancer cells. On the contrary, Tan et al. (2018) have shown the CXXC5 promotes HCC malignancies by stimulating the proliferation, migration, and invasion of liver cancer cells. It remains to be determined whether and, if so, how CXXC5 may regulate the trans-differentiation of HSCs during liver fibrosis. Of note, Lee S.H. et al. (2015) have demonstrated that CXXC5-null mice display accelerated subcutaneous wound healing. Mechanistically, CXXC5 binds to the Dishevelled protein to promote β-catenin degradation thus blocking Wnt-mediated myofibroblast activation. We therefore hypothesized that CXXC5 might regulate HSC trans-differentiation. We report here that CXXC5 expression is down-regulated during HSC activation. On the contrary, CXXC5 over-expression antagonizes HSC activation. CXXC5 binds to the promoter region of MYCL1, a proto-oncogene, and represses MYCL1 transcription. Loss of CXXC5 leads to MYCL1 depression and HSC activation.

**MATERIALS AND METHODS**

**Animals**

All the animal experiments were reviewed and approved by the Nanjing Medical University Ethics Committee on Humane Treatment of Laboratory Animals. To induce liver fibrosis, male C57BL/6 mice were injected with CCl₄ (1.0 mL/kg as 50% vol/vol) or subjected to bile duct ligation (BDL) as previously described (Wang Q. et al., 2020; Li et al., 2021). Picrosirius red staining was performed with paraffin-embedded liver sections using a commercially available kit (Sigma Aldrich) as previously described (Li et al., 2021). For hydroxyproline quantification, ~10 mg of liver tissue was weighed, homogenized, and hydrolyzed in HCl (10N) at 120°C for 3 h. Supernatants were transferred to a 96-well plate and hydroxyproline content was determined by colorimetry (Sigma Aldrich, MAK008).

**Cell Culture, Plasmids, and Transient Transfection**

Immortalized human hepatic stellate cells (LX-2) were maintained in DMEM supplemented with 10% FBS. Primary hepatic stellate cells were isolated and maintained as previously described (Jin et al., 2020; Lv et al., 2020; Wu et al., 2020). Briefly, the animals were anesthetized by intraperitoneal injection with ketamine-xylazine. A laparotomy was performed and the portal vein was cut to allow retrograde perfusion with pronase (Sigma Aldrich, St. Louis, MO, United States) and collagenase (Roche, Germany) containing solutions. HSCs were isolated from the non-parenchymal fraction by 9.7% Nycodenz gradient centrifugation. Isolated HSCs were seeded in plastic culture dishes and allowed to undergo spontaneous activation. RNA targeting SRF (GAUGGAGUUCAUCGACAACAA) was purchased from Dharmacon. Recombinant TGF-β1 (100-21) was purchased from Peprotech. Transient transfections were performed with Lipofectamine 2000. Luciferase activities were assayed 24–48 h after transfection using a luciferase reporter assay system (Promega) as previously described (Yang et al., 2019a,b).

**Protein Extraction and Western Blot**

Whole cell lysates were obtained by re-suspending cell pellets in RIPA buffer (50 mMTris pH7.4, 150 mMNaCl, 1% Triton X-100) with freshly added protease inhibitor (Roche) as previously described (Yang et al., 2019a,b). Western blot analyses were performed with anti-CXXC5 (Cell Signaling Tech, 84546), anti-MYCL1 (Abcam, ab28739), anti-α-SMA (Abcam, ab5694), and anti-β-actin (Sigma, A1978). For densitometrical quantification, densities of target proteins were normalized to those of β-actin. Data are expressed as relative protein levels compared to the control group which is arbitrarily set as 1.

**RNA Isolation and Real-Time PCR**

RNA was extracted with the RNeasy DNA isolation kit (Qiagen). Reverse transcriptase reactions were performed using a SuperScript First-strand Synthesis System (Invitrogen) as previously described. Real-time PCR reactions were performed on an ABI Prism 7500 system with the following primers: human CXXC5, 5′-CGGTGGACAAAAAGCAACCCCTAC-3′ and 5′-CGCTTCAGCATCTCTGTGGACT-3′; mouse Cxxc5, 5′-GTCC GAGGAGGCCAGAG-3′ and 5′-CGCTGCCCACAATAGA GAT-3′; human ACTA2, 5′-CTATGGCCTTGGACGACAAC-3′ and 5′-CAGATCCAGCGCATGGCA-3′; mouse Acta2,
RNA Sequencing and Data Analysis
Total RNA was extracted using the TRIzol reagent according to the manufacturer's protocol. RNA purity and quantification were evaluated using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, United States). RNA integrity was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, United States). Then the libraries were constructed using TruSeq Stranded mRNA LT Sample Prep Kit (Illumina, San Diego, CA, United States) according to the manufacturer's instructions and sequenced on an Illumina HiSeq X Ten platform (Illumina, San Diego, CA, United States) according to the manufacturer's protocol. RNA purity and quantification were arbitrarily set as 1.

Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) assays were performed essentially as described before (Coarfa et al., 2020; Maity et al., 2020; Wang J.N. et al., 2020; Wang S. et al., 2020; Marti et al., 2021). In brief, chromatin in control and treated cells were cross-linked with 1% formaldehyde. Cells were incubated in lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) supplemented with protease inhibitor tablet and phenylmethylsulfonyl fluoride (PMSF). DNA was fragmented into ~200 bp pieces using a Branson 250 sonicator. Aliquots of lysates containing 200 μg of protein were used for each immunoprecipitation reaction with anti-CXXC5 (Proteintech, 16513-1), anti-5′-methylcytosine (Abcam, ab214727), anti-acetyl H3K9 (Millipore, 07-352), anti-acetyl H3K27 (Millipore, 07-360), anti-RNA polymerase II CTD p-Ser2 (Abcam, ab138246), anti-RNA polymerase II CTD p-Ser5 (Abcam, ab252852), or pre-immune IgG. Precipitated DNA was amplified with the following primers: MYCL1 primer#1: 5′-AACCTGTCGACTGCGTGAAGA-3′ and 5′-AGCCAGCACACACGACAT-3′; MYCL1 primer#2, 5′-ATCGTGAAGATGAC-3′ and 5′-AGGTCTCACCAGCAGCACC-3′; ITGB4 primer, 5′-CTCGGACAGTCCCTGTGCTC-3′ and 5′-GCTGCGCTTAGGATGATGGAAGCATAATTCCTGC-3′. Ct values of target genes were normalized to the Ct values of housekeeping control gene (18s, 5′-CGCGGTCTTCTATTTTGTG-3′ and 5′-CTCTTCAAGAATCATCCGACT-3′ for both human and mouse genes) using the ΔΔCt method and expressed as relative mRNA expression levels compared to the control group which is arbitrarily set as 1.

RESULTS

Down-Regulation of CXXC5 Expression Parallels Hepatic Stellate Cell Activation
We first evaluated the relationship between CXXC5 expression and HSC activation in different animal and cell models of liver fibrosis. In the first model liver fibrosis was induced in mice by BDL; liver fibrosis was evident as examined by picrosirius red staining (Figure 1A, left panel) and hydroxyproline quantification (Figure 1A, right panel). As shown in Figure 1B, mRNA expression of α-SMA (Acta2), a myofibroblast marker, was significantly up-regulated in primary HSCs isolated from the BDL mice compared to the sham mice indicative of HSC activation/trans-differentiation; accompanying Acta2 up-regulation, there was a simultaneous down-regulation of CXXC5 mRNA. Western blotting showed that CXXC5 protein levels were also decreased in the primary HSCs isolated from the fibrotic livers compared to the normal livers (Figure 1C). In the second model in which the mice were injected with carbon tetrachloride (CCl₄), robust liver fibrosis was detected by picrosirius red staining (Figure 1D, left panel) and hydroxyproline quantification (Figure 1D, right panel). Similarly, it was found that CXXC5 expression was down-regulated in the HSCs isolated from the fibrotic livers compared to the control livers (Figures 1E,F).
FIGURE 1 | Down-regulation of CXXC5 expression parallels hepatic stellate cell activation. (A–C) C57/B6 mice were subjected to the BDL or the sham procedure for 2 weeks as described in section “Materials and Methods.” (A) Liver fibrosis was confirmed by picrosirius red staining and hydroxylproline quantification. Primary hepatic stellate cells were isolated and CXXC5 expression levels were examined by qPCR (B) and Western (C). (D–F) C57/B6 mice were injected with or without CCl₄ for 4 weeks as described in section “Materials and Methods.” (D) Liver fibrosis was confirmed by picrosirius red staining and hydroxylproline quantification. Primary hepatic stellate cells were isolated and CXXC5 expression levels were examined by qPCR (E) and Western (F). N = 6–10 mice for each group. (G,H) Primary hepatic stellate cells were isolated from C57/B6 mice and allowed to undergo spontaneous activation in culture. CXXC5 expression levels were examined by qPCR and Western. (I,J) LX-2 cells were treated with or without TGF-β1 (2 ng/ml). The cells were harvested at indicated time points and CXXC5 expression levels were examined by qPCR and Western. All experiments were repeated three times and one representative experiment is shown. *p < 0.05.
When primary HSCs were cultured in vitro and underwent spontaneous activation, there was a progressive elevation of Acta2 expression and a simultaneous down-regulation of Cxxc5 expression at both mRNA (Figure 1G) and protein (Figure 1H) levels. In human immortalized HSCs (LX-2), TGF-β expression and a simultaneous down-regulation of spontaneous activation, there was a progressive elevation of pro-fibrogenic genes including collagen type I, collagen type III, connective tissue growth factor, and tissue inhibitor of metalloproteinase (Figures 2A,B). In addition, CXXC5 over-expression dampened the levels of several well-documented pro-fibrogenic genes including collagen type I, collagen type III, connective tissue growth factor, and tissue inhibitor of metalloproteinase (Figures 2A,B). Using p value <0.05 and fold change >2 or fold change <0.5 as cutoffs, we were able to identify 58 genes down-regulated and 106 genes up-regulated by CXXC5 over-expression (Figures 3B,C). GO (Figure 3D) and KEGG (Figure 3E) analyses showed that several pathways related to liver fibrosis including PI3K-AKT signaling, ECM–receptor interaction, and focal adhesion were altered due to CXXC5 over-expression. Because many studies agree that CXXC5 primarily functions as a transcriptional repressor (Andersson et al., 2009; L’Hote et al., 2012), we focused on the genes repressed by CXXC5 over-expression. Several genes, including NCF (Rasi et al., 2007) and NOTCH3 (Chen et al., 2012), have been investigated for their roles in the pathogenesis of liver fibrosis. A definitive role for the others, including the proto-oncogene MYCL1, in HSC activation remains undetermined. On the contrary, over-expression of CXXC5 repressed the induction of MYCL1 expression by TGF-β1 treatment in LX-2 cells (Figures 4G,H). More importantly, ChIP assay showed that CXXC5 could directly bind to the CpG island region located surrounding the transcription start site (TSS) of the MYCL1 promoter; TGF-β1 treatment, however, severely dampened the occupancy of CXXC5 on the MYCL1 promoter (Figure 4I). By comparison, no binding of CXXC5 was detected on the ITGB4 promoter with no CpG island, suggesting that CXXC5 might repress ITGB4 expression indirectly (Supplementary Figure 2). On the contrary, removal of CXXC5 binding from the MYCL1 promoter upon TGF-β1 stimulation coincided with the erasure of DNA methylation (5′-methylcytosine) and accumulation of acetylated histone H3K9/H3K27 (Figure 4J) indicative of active chromatin remodeling. TGF-β1 treatment significantly augmented the enrichment of Pol II CTD Ser5 on the CXXC5 promoter region indicative of accelerated transcriptional initiation. There was a comparatively smaller but significant increase in the association of Pol II CTD Ser2 with the CXXC5 gene body, which may reflect secondarily enhanced elongation (Figure 4K).

**MYCL1 Is a Novel CXXC5 Target**

C-MYC, the founding member of the MYC family of proto-oncogenes, has a well-established role in HSC activation and liver fibrosis (Potter et al., 1999; Nezvortova et al., 2013; Arteaga et al., 2016; Cai et al., 2018). In contrast, relatively little is known regarding the role of I-MYC (encoded by MYL1 or MYCL), a closely related sibling of C-MYC. Therefore, we examined the regulation of MYCL1 expression by CXXC5 and its relevance in HSC activation. As shown in Figures 4A,B, MYCL1 expression was markedly induced by TGF-β1 treatment mirroring the down-regulation of CXXC5. MYCL1 expression, at both mRNA (Figure 4C) and protein (Figure 4D) levels, was higher in the activated HSCs isolated from the BDL mice than in the quiescent HSCs isolated from the sham mice. Similarly, it was also observed that MYCL1 expression was up-regulated in the HSCs isolated from the mice subjected to CCl4 injection compared to those isolated from the mice injected with corn oil (Figures 4E,F). On the contrary, over-expression of CXXC5 repressed the induction of MYCL1 expression by TGF-β1 treatment in LX-2 cells (Figures 4G,H). More importantly, ChIP assay showed that CXXC5 could directly bind to the CpG island region located surrounding the transcription start site (TSS) of the MYCL1 promoter; TGF-β1 treatment, however, severely dampened the occupancy of CXXC5 on the MYCL1 promoter (Figure 4I). By comparison, no binding of CXXC5 was detected on the ITGB4 promoter with no CpG island, suggesting that CXXC5 might repress ITGB4 expression indirectly (Supplementary Figure 2). Of interest, removal of CXXC5 binding from the MYCL1 promoter upon TGF-β1 stimulation coincided with the erasure of DNA methylation (5′-methylcytosine) and accumulation of acetylated histone H3K9/H3K27 (Figure 4J) indicative of active chromatin remodeling. TGF-β1 treatment significantly augmented the enrichment of Pol II CTD Ser5 on the CXXC5 promoter region indicative of accelerated transcriptional initiation. There was a comparatively smaller but significant increase in the association of Pol II CTD Ser2 with the CXXC5 gene body, which may reflect secondarily enhanced elongation (Figure 4K).

**DISCUSSION**

Expansion and trans-differentiation of quiescent hepatic stellate cells into mature myofibroblasts represent a hallmark event in...
liver fibrosis. Here we describe a novel role for the transcriptional regulator CXXC5 in HSC activation (Figure 5G). We show here that CXXC5 down-regulation correlates with HSC activation in vivo and in vitro. It remains unclear what mechanism may account for the repression of CXXC5 expression. Grimwade and colleagues have argued that promoter methylation of
CXXC5 contributes to its down-regulation in patients with acute myeloid leukemia (AML; Kuhnl et al., 2015). Because all three isoforms of DNA methyltransferases (DNMTs) are activated during HSC trans-differentiation (Gotze et al., 2015), it is reasonable to postulate that CXXC5 repression may result from DNMT-mediated hypermethylation. Alternatively, Yasar et al. (2016) have reported that estradiol, through estrogen receptor (ER), activates CXXC5 transcription in breast cancer cells. Since the E2-ER axis plays an inhibitory role in HSC activation and liver fibrosis (Zhang et al., 2018), it is tempting to speculate...
FIGURE 4 | MYCL1 is a novel CXXC5 target. (A,B) LX-2 cells were treated with or without TGF-β1 (2 ng/ml). The cells were harvested at indicated time points and MYCL1 expression levels were examined by qPCR and Western. (C,D) C57/B6 mice were injected with or without CCl\textsubscript{4} for 4 weeks as described in section “Materials and Methods.” Primary hepatic stellate cells were isolated and CXXC5 expression levels were examined by qPCR and Western. N = 6 mice for each group. (E,F) C57/B6 mice were subjected to the BDL or the sham procedure for 2 weeks as described in section “Materials and Methods.” Primary hepatic stellate cells were isolated and CXXC5 expression levels were examined by qPCR and Western. N = 6 mice for each group. (G,H) LX-2 cells were infected with infected with adenovirus carrying CXXC5 expression vector (Ad-CXXC5) or GFP (Ad-GFP) followed by TGF-β1 (2 ng/ml) treatment for 48 h. MYCL1 expression was examined by qPCR and Western. (I) LX-2 cells were treated with or without TGF-β1 (2 ng/ml). The cells were harvested at indicated time points and ChIP assay was performed with anti-CXXC5 or IgG. (J) LX-2 cells were treated with or without TGF-β1 (2 ng/ml). The cells were harvested at indicated time points and ChIP assay was performed with anti-5′-methylcytosine, anti-acetyl H3K9, or anti-acetyl H3K27. (K) LX-2 cells were treated with or without TGF-β1 (2 ng/ml). The cells were harvested at indicated time points and ChIP assay was performed with anti-RNA Pol II (ser5) and anti-RNA Pol II (ser2). All experiments were repeated three times and one representative experiment is shown. *p < 0.05.
FIGURE 5 | MYCL1 promotes HSC activation. (A–C) LX-2 cells were infected with indicated adenovirus. Gene expression levels were examined by qPCR and Western. Cell proliferation was measured by EdU staining. (D–F) LX-2 were transfected siRNA targeting MYCL1 or scrambled siRNA (SCR) followed by treatment with TGF-β (2 ng/ml). Gene expression levels were examined by qPCR and Western. Cell proliferation was measured by EdU staining. All experiments were repeated three times and one representative experiment is shown. (G) A schematic model. *p < 0.05.
that CXXC5 repression may be secondary to dampened E2-ER signaling.

Although we provide data to show that CXXC5 over-expression antagonizes HSC trans-differentiation, the in vivo relevance of this finding remains to be ascertained. CXXC5-null mice are viable and display no other overt phenotypes than enlargements of the skull, scapula, spine, ribs, and limb bones (Kim et al., 2015), suggesting that CXXC5 is unlikely a major contributor to hepatic homeostasis under physiological conditions. On the other hand, Cheng et al. (2020) have demonstrated that CXXC5 knockdown, achieved by adenovirus carrying CXXC5-targeting shRNA, attenuates bleomycin-induced pulmonary fibrosis in mice possibly owing to increased apoptosis of lung fibroblasts although the specificity of this system remains questionable. More recently, it has been shown that CXXC5 regulates the phenotype of plasmacytoid dendritic cells (pDCs) by functioning as a transcriptional repressor of the pro-inflammatory protein IRF7 (Ma et al., 2017). Of interest, Wu et al. (2019) have reported that IRF7 bridges inflammation to fibrogenesis by interacting with SMAD3, a key mediator of TGF-β signaling and that IRF7 knockout mice are protected from systemic sclerosis, a prototypical form of inflammation-associated tissue fibrosis. Because CXXC5 deficiency leads to IRF7 up-regulation in mice (Ma et al., 2017), which may potentially trigger a pro-fibrogenic response, it would be of great help to examine the phenotype of the CXXC5-null mice in the settings of the liver fibrosis. Although our data indicate that CXXC5 may regulate proliferation and expression of pro-fibrogenic genes in HSCs, other potential mechanisms are not fully examined. For instance, it has been proposed that accelerated apoptosis of HSCs may be considered as an approach to mitigate or reverse liver fibrosis (Elsharkawy et al., 2005). Previous studies have shown that CXXC5 promote apoptosis in neurons and cancer cells by amplifying the TGF-β-SMAD pathway (Wang et al., 2013; Yan et al., 2018). Therefore, it is possible that CXXC5 may regulate HSC phenotype by skewing the death-survival balance.

Through RNA-seq, we have identified the proto-oncogene MYCL1 as a direct transcriptional target for CXXC5. Further, we demonstrate here that MYCL1 activates expression of pro-fibrogenic genes and promotes cell proliferation in HSCs. MYCL1 belongs to the myelocytomatosis (MYC) family of multifaceted transcription regulators sharing significant homology with c-MYC and MYCN (Bragelmann et al., 2017). Prior to our investigation, no evidence existed to link MYCL1 to HSC activation and/or liver fibrosis. Mounting evidence suggests that MYCL1 hyperactivation is associated with augmented proliferation in malignant cancer cells (Diolaiti et al., 2015; Suzuki et al., 2016; Kamibeppu et al., 2018). For instance, MacPherson and colleagues have discovered that lung cancer cells originated from MYCL1-null mice exhibited slower proliferation than those from the wild type mice and are unable to form malignant tumors (Kim et al., 2016). In addition, targeted inhibition of cancer cell proliferation appears to correlate with down-regulation of MYCL1 expression (Kato et al., 2016). However, no consensus has emerged from previous studies with regard to the exact mechanism whereby MYCL1 regulates cellular proliferation. Based on RNA-seq analysis of lung cancer cell transcriptome driven by MYCL1 over-expression, Kim et al. (2016) have proposed that MYCL1 may stimulate cell proliferation by orchestrating RNA polymerase I-dependent ribosomal RNA synthesis. There is evidence to suggest that the rRNA synthesis pathway is involved in HSC activation (Lechuga et al., 2004; Yang et al., 2009; Morales-Ibanez et al., 2016). Presumably MYCL1 contributes to HSC proliferation via a similar mechanism but this hypothesis clearly warrants further investigation. Recently, Wakao et al. (2017) have presented evidence that over-expression of MYCL1 in human fibroblasts induces a muscle-like phenotype. This observation provides support for our finding that MYCL1 may be involved in the acquisition of a contractile phenotype characteristic to HSC trans-differentiation although the mechanism is not clear. Similar to CXXC5, MYCL1 deficiency in mice is compatible with embryogenesis suggesting that MYCL1, like CXXC5, is not required to maintain the quiescence of the HSC population (Hatton et al., 1996). It would be of high interest to determine how MYCL1 deletion would influence liver fibrosis in mice.

Our data show that de-repression of MYCL1 transcription by CXXC5 down-regulation is associated with erasure of DNA methylation and accumulation of histone acetylation on the MYCL1 promoter. Tsuchiya et al. (2016) have reported that CXXC5 can interact with the H3K9 trimethyltransferase SUV39H1 in T lymphocytes to repress Cd40lg transcription. On the one hand, a coordination between SUV39H1-dependent H3K9 trimethylation and DNA methylation is well documented (Cedar and Bergman, 2009). Thus, it is conceivably that CXXC5 may recruit SUV39H1 to the MYCL1 promoter, which consequently enlists DNMTs to catalyze CpG methylation. In addition, because H3K9 methylation is antagonistic to H3K9 acetylation, removal of CXXC5 from the MYCL1 may dampen SUV39H1 recruitment and H3K9 methylation, which may secondarily up-regulate H3K9 acetylation. On the other hand, CXXC5 can directly interact with histone deacetylase 1 (HDAC1) to regulate the TGF-β signaling (Yan et al., 2018). It is possible that departure of CXXC5 from the MYCL1 promoter steers away the HDACs and histone acetylation then increases as a result. Clearly, further elucidation of the detailed epigenetic mechanism underlying MYCL1 trans-activation may shed additional light on the role of CXXC5 as a regulator of HSC trans-differentiation.

In summary, our data identify a CXXC5-MYCL1 axis that contributes to HSC activation. Screening for small-molecule compounds that boost CXXC5 activity could potentially yield novel therapeutic strategies in the intervention of liver fibrosis.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are publicly available. These data can be found in the PUBMED BioProject database, accession number PRJRNA733841.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Nanjing Medical University Ethics Committee on Humane Treatment of Experimental Animals.
AUTHOR CONTRIBUTIONS

XS and WZ conceived the project, secured funding, and provided supervision. XW, WD, and MK designed the experiments. XW, WD, MK, HR, JW, LS, and ZZ performed the experiments and collected the data. All authors wrote the manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (81872359 and 81670566), Jiangsu Province’s Key Provincial Talents Program (ZDRCA2016066), the Nanjing Medical Science and Technology Development Foundation (QRX17129), the Nanjing Health Science and Technology Development Project for Distinguished Young Scholars (JQX19002), the Nanjing Science and Technology Project (201911039), and Innovation and the Entrepreneurship Education Incubation Project of Nanjing University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.680344/full#supplementary-material
altering mitochondrial metabolism.

derived stem cell differentiation through the induction of mitophagy and

redox.2020.101622

antagonizes hepatic stellate cell activation and liver fibrosis by modulating ROS

levels.

mitochondria in liver fibrosis independent of its aetiology.

Redox Biol.

HIF-1alpha-

potential mediator of liver fibrogenesis.

Gut

J. Leukoc. Biol.

repression of CD40L expression in CD8+ cytotoxic T cells.

Anticancer Drugs

M. (2016). Antimyeloma activity of bromodomain inhibitors on the human

myeloma cell line U266 by downregulation of MYCL.

Y asar, P., Ayaz, G., and Muyan, M. (2016). Estradiol-estrogen receptor alpha

mediates the expression of the CXXC5 gene through the estrogen response

element-dependent signaling pathway.

Sci. Rep.

2017.38

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wu, Dong, Kong, Ren, Wang, Shang, Zhu, Zhu and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.